CORDIS
EU research results

CORDIS

English EN
Autism Innovative Medicine Studies – 2 – Trials

Autism Innovative Medicine Studies – 2 – Trials

Objective

Autism Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental condition affecting over five million people in the European Union. The combination of core symptoms (deficits in social-communication and repetitive and restricted behaviours and interests) and common comorbidities (e.g. epilepsy and depression) significantly reduces the quality of life and life-span of affected individuals. Currently there are no effective drug treatments for the core symptoms. Key factors that have hampered progress include; 1) limited understanding of the underlying pathophysiolog(ies); 2) lack of successful translation from animal models to humans; 3) testing of drugs with specific actions in biologically heterogeneous populations; 4) limited expertise of many European ASD centres in running large-scale clinical trials; and 5) trial designs (e.g. placebo effects).

Our vision, therefore, is to apply a precision medicine approach to ASD and improve patient outcomes by tailoring treatments to a patient’s biological profile. Our efforts will build on the achievements of 5 other IMI initiatives, 4 Horizon 2020 networks, and 6 SMEs for the first time to; 1) align global resources to validate and qualify stratification biomarkers from infancy to adulthood; 2) develop objective outcome measures that can be used in trials; 3) create a European-wide clinical trials network that reliably carries out studies able to support filings to the EMA/FDA; 4) carry out better targeted clinical trials linked to other international efforts – including quick wins or “fast fails” of ineffective agents; 5) translate molecular mechanisms and drug effects between preclinical models and particular subtypes of ASD.

Together we will bring Europe to the forefront of clinical research in ASD. Also we will provide a sustainable legacy that is accessible by others across the world, attracts industry into ASD, and helps transform healthcare.

Coordinator

KING'S COLLEGE LONDON

Address

Strand
Wc2r 2ls London

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 20 060 301,45

Participants (47)

Sort alphabetically

Sort by EU Contribution

Expand all

F. HOFFMANN-LA ROCHE AG

Switzerland

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 2 808 025

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 4 635 793,75

SERVICIO MADRILENO DE SALUD

Spain

EU Contribution

€ 5 502 025

INSTITUT PASTEUR

France

EU Contribution

€ 2 817 987,50

UNIVERSITAT BASEL

Switzerland

EU Contribution

€ 1 205 000

ZENTRALINSTITUT FUER SEELISCHE GESUNDHEIT

Germany

EU Contribution

€ 924 135

BIOSCI CONSULTING

Belgium

EU Contribution

€ 192 343,75

RIJKSUNIVERSITEIT GRONINGEN

Netherlands

EU Contribution

€ 837 500

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 805 000

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 807 500

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 305 000

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 296 625

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

Ireland

EU Contribution

€ 392 346,25

BIRKBECK COLLEGE - UNIVERSITY OF LONDON

United Kingdom

EU Contribution

€ 2 899 831,25

STICHTING BURO ECNP

Netherlands

EU Contribution

€ 187 498,75

NOLDUS INFORMATION TECHNOLOGY BV

Netherlands

EU Contribution

€ 272 500

ARTTIC

France

EU Contribution

€ 549 525

DEMCON ADVANCED MECHATRONICS BV

Netherlands

EU Contribution

€ 482 500

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 1 350 196,25

JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN

Germany

EU Contribution

€ 783 500

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

EU Contribution

€ 961 942,50

UNIVERSITEIT GENT

Belgium

EU Contribution

€ 1 187 320

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EU Contribution

€ 305 000

UNIVERSITAET ULM

Germany

EU Contribution

€ 805 577,50

CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS

France

EU Contribution

€ 68 125

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN

Germany

EU Contribution

€ 202 500

Fondazione Stella Maris

Italy

EU Contribution

€ 68 125

UNIVERSIDAD DE SALAMANCA

Spain

EU Contribution

€ 68 125

UNIVERSITY OF GLASGOW

United Kingdom

EU Contribution

€ 305 000

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

EU Contribution

€ 916 023,75

UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS

Germany

EU Contribution

€ 68 125

STELLENBOSCH UNIVERSITY

South Africa

EU Contribution

€ 419 543,75

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 149 995

UNIVERSIDADE DE COIMBRA

Portugal

EU Contribution

€ 780 299,80

FUNDAZIOA POLICLINICA GIPUZKOA FUNDACION

Spain

EU Contribution

€ 68 125

FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA

Spain

EU Contribution

€ 68 125

JANSSEN PHARMACEUTICA NV

Belgium

NOVARTIS PHARMA AG

Switzerland

UCB BIOPHARMA SPRL

Belgium

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Israel

AUTISM SPEAKS INC. NON PROFIT CORPORATION

United States

THE SIMONS FOUNDATION, INC

United States

AUTISTICA

United Kingdom

AUTISME-EUROPE AISBL

Belgium

EU Contribution

€ 268 600

UNIVERSITY OF BRISTOL

United Kingdom

EU Contribution

€ 51 812,50

STARLAB BARCELONA SL

Spain

EU Contribution

€ 122 500

Project information

Grant agreement ID: 777394

Status

Ongoing project

  • Start date

    1 June 2018

  • End date

    31 May 2023

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 113 274 914,75

  • EU contribution

    € 54 999 998,75

Coordinated by:

KING'S COLLEGE LONDON

United Kingdom